545 related articles for article (PubMed ID: 33347998)
1. Clinical outcomes of polymer-free, paclitaxel-coated stents vs stent grafts in peripheral arterial disease patients with femoropopliteal artery lesions.
Tsujimura T; Takahara M; Iida O; Soga Y; Katsuki T; Fujihara M; Kawasaki D; Kozuki A; Mano T
J Vasc Surg; 2021 Jun; 73(6):1998-2008.e1. PubMed ID: 33347998
[TBL] [Abstract][Full Text] [Related]
2. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions.
Bosiers M; Setacci C; De Donato G; Torsello G; Silveira PG; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Teβarek J; Giaquinta A; Wauters J
J Endovasc Ther; 2020 Apr; 27(2):287-295. PubMed ID: 31997715
[No Abstract] [Full Text] [Related]
3. A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.
Gouëffic Y; Sauguet A; Desgranges P; Feugier P; Rosset E; Ducasse E; Kaladji A; Salomon du Mont L; Pernès JM; Commeau P; Lermusiaux P; Leclere B; Guyomarc'h B; Hoffmann CT; Maurel B
JACC Cardiovasc Interv; 2020 Feb; 13(4):447-457. PubMed ID: 32081238
[TBL] [Abstract][Full Text] [Related]
4. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
Ichihashi S; Shibata T; Fujimura N; Nagatomi S; Yamamoto H; Kyuragi R; Adachi A; Iwakoshi S; Bolstad F; Saeki K; Obayashi K; Kichikawa K
J Endovasc Ther; 2019 Oct; 26(5):613-620. PubMed ID: 31257994
[No Abstract] [Full Text] [Related]
5. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
Ullery BW; Tran K; Itoga N; Casey K; Dalman RL; Lee JT
J Vasc Surg; 2015 Jun; 61(6):1479-88. PubMed ID: 25704407
[TBL] [Abstract][Full Text] [Related]
6. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Tran K; Ullery BW; Kret MR; Lee JT
Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
[TBL] [Abstract][Full Text] [Related]
7. 1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.
Iida O; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1105-1112. PubMed ID: 26117463
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Multicenter Comparison Between Viabahn Covered Stent-Grafts and Supera Interwoven Nitinol Stents for Endovascular Treatment in Severely Calcified Femoropopliteal Artery Disease: The ARMADILLO Study (Adjusted Retrospective coMparison of scAffolDs In caLcified LesiOns).
Horie K; Takahara M; Nakama T; Tanaka A; Tobita K; Hayakawa N; Mori S; Iwata Y; Suzuki K
J Endovasc Ther; 2024 Jun; 31(3):400-409. PubMed ID: 36146948
[TBL] [Abstract][Full Text] [Related]
9. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
[TBL] [Abstract][Full Text] [Related]
10. Viabahn Stent Graft for the Endovascular Treatment of Occlusive Lesions in the Femoropopliteal Artery: A Retrospective Cohort Study with 4-Year Follow-Up.
Ni Q; Yang S; Xue G; Zhou Z; Zhang L; Ye M
Ann Vasc Surg; 2020 Jul; 66():573-579. PubMed ID: 31743785
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel exposure and long-term mortality of patients treated with the Zilver PTX drug-eluting stent.
Stern JR; Tran K; Chandra V; Harris EJ; Lee JT
Vascular; 2021 Aug; 29(4):567-573. PubMed ID: 33054678
[TBL] [Abstract][Full Text] [Related]
12. Mortality Risk Following Application of a Paclitaxel-Coated Stent in Femoropopliteal Lesions.
Katsuki T; Takahara M; Soga Y; Okamoto S; Iida O; Fujihara M; Kawasaki D; Ando K
J Endovasc Ther; 2019 Oct; 26(5):593-599. PubMed ID: 31431154
[TBL] [Abstract][Full Text] [Related]
13. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial.
Gray WA; Keirse K; Soga Y; Benko A; Babaev A; Yokoi Y; Schroeder H; Prem JT; Holden A; Popma J; Jaff MR; Diaz-Cartelle J; Müller-Hülsbeck S;
Lancet; 2018 Oct; 392(10157):1541-1551. PubMed ID: 30262332
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions.
Ohki T; Kichikawa K; Yokoi H; Uematsu M; Yamaoka T; Maeda K; Kanaoka Y
J Vasc Surg; 2017 Jul; 66(1):130-142.e1. PubMed ID: 28400218
[TBL] [Abstract][Full Text] [Related]
15. One-Year Late Lumen Loss between A Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) and a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) for Femoropopliteal Disease.
Soga Y; Fujihara M; Tomoi Y; Iida O; Ishihara T; Kawasaki D; Ando K
J Atheroscler Thromb; 2020 Feb; 27(2):164-171. PubMed ID: 31257301
[TBL] [Abstract][Full Text] [Related]
16. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Zilver PTX stent implantation for the treatment of complex femoropopliteal artery disease.
Fujihara M; Utsunomiya M; Higashimori A; Yokoi Y; Nakamura M
Heart Vessels; 2016 Feb; 31(2):152-7. PubMed ID: 25351136
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of the Japanese multicenter Viabahn trial of heparin bonded endovascular stent grafts for long and complex lesions in the superficial femoral artery.
Ohki T; Kichikawa K; Yokoi H; Iida O; Yamaoka T; Maeda K; Kanaoka Y
J Vasc Surg; 2021 Dec; 74(6):1958-1967.e2. PubMed ID: 34182032
[TBL] [Abstract][Full Text] [Related]
19. Prediction Model for Freedom from TLR from a Multi-study Analysis of Long-Term Results with the Zilver PTX Drug-Eluting Peripheral Stent.
Dake MD; Fanelli F; Lottes AE; O'Leary EE; Reichert H; Jiang X; Fu W; Iida O; Zen K; Schermerhorn M; Zeller T; Ansel GM
Cardiovasc Intervent Radiol; 2021 Feb; 44(2):196-206. PubMed ID: 33025243
[TBL] [Abstract][Full Text] [Related]
20. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
